China's significant control over the global supply of active pharmaceutical ingredients (APIs) presents a national security risk to the United States, according to recent analyses. While the U.S. produces approximately 3% of the world's APIs, China manufactures a substantial 45%. A Johns Hopkins study indicated that China supplies over 60% of the essential components required by American manufacturers for antibiotics.
This dependency has been described as a "pharma choke point" by the Council on Foreign Relations, with reliance extending from generic drugs to advanced biologics. Decades of offshoring have eroded the American industrial base, shifting critical manufacturing jobs overseas. In 1981, the United States produced 25% of global pharmaceutical ingredients, a stark contrast to the current landscape where China dominates nearly half the market.
Fentanyl Pipeline and Supply Chain Vulnerabilities
The same chemical supply networks that feed pharmaceutical precursors into the U.S. also fuel the illicit fentanyl pipeline through Mexico. Research from the University of Virginia’s National Security Data and Policy Institute highlights a symbiotic relationship between Chinese suppliers and Mexican cartels. This adaptive supply chain involves purchasing precursors online, air-shipping them in bulk, converting them into pills, and smuggling them across the border. A relatively small investment in chemicals can yield millions of doses of fentanyl, contributing to the devastating impact seen in American communities.
This reliance on China for pharmaceuticals is compared to its weaponization of supply chains for rare earths, semiconductor inputs, and defense-critical metals. Concerns have been raised about whether the Chinese Communist Party would hesitate to weaponize the pharmaceutical supply in a crisis, given its capacity to influence the availability and safety of essential medications.
Legislative and Industrial Responses
In response to these vulnerabilities, Congress has begun to take action. The BIOSECURE Act, enacted in December 2025, restricts federal procurement of biotechnology products from companies linked to foreign adversaries. Former President Donald Trump also implemented executive actions, including tariffs targeting the synthetic opioid supply chain. However, these measures are seen as insufficient to rebuild domestic manufacturing capacity.
To effectively reduce China's hold on the U.S. pharmaceutical supply chain, significant investment in domestic production is required. States like Ohio are being highlighted as models, demonstrating success in rebuilding American semiconductor manufacturing through a combination of investment, infrastructure development, and workforce cultivation. Experts suggest that Ohio possesses similar potential to become a national hub for pharmaceutical production by incentivizing American companies to establish advanced manufacturing facilities in the Midwest. Such a strategy would not only create secure jobs but also address a critical defense vulnerability.
Securing Medical Independence
The nation faces a choice: invest in domestic pharmaceutical capacity now or face potentially severe consequences if Beijing decides to weaponize the U.S. medicine supply. Ensuring border security is complicated by Chinese chemical suppliers arming cartels, and military readiness is hampered when battlefield antibiotics rely on manufacturing in a potential adversary nation. Ultimately, the safety of the American people is compromised when their access to essential medicines is dependent on the goodwill of a foreign power. Building domestic manufacturing plants and prioritizing medical independence are presented as crucial steps to safeguard national security.